{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:39:19Z","timestamp":1770971959425,"version":"3.50.1"},"reference-count":135,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Lymphomas encompass a diverse group of malignant lymphoid neoplasms. Over recent years much scientific effort has been undertaken to identify and understand molecular changes in lymphomas, resulting in a wide range of genetic alterations that have been reported across all types of lymphomas. As many of these changes are now incorporated into the World Health Organization\u2019s defined criteria for the diagnostic evaluation of patients with lymphoid neoplasms, their accurate identification is crucial. Even if many alterations are not routinely evaluated in daily clinical practice, they may still have implications in risk stratification, treatment, prognosis or disease monitoring. Moreover, some alterations can be used for targeted treatment. Therefore, these advances in lymphoma molecular diagnostics in some cases have led to changes in treatment algorithms. Here, we give an overview of and discuss advances in molecular techniques in current clinical practice, as well as highlight some of them in a clinical context.<\/jats:p>","DOI":"10.3390\/diagnostics11122174","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T02:46:08Z","timestamp":1637721968000},"page":"2174","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Advances in Lymphoma Molecular Diagnostics"],"prefix":"10.3390","volume":"11","author":[{"given":"Igor Age","family":"Kos","sequence":"first","affiliation":[{"name":"Department of Hematology, Oncology, Clinical Immunology, Rheumatology, Medical School, University of Saarland, 66424 Homburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenz","family":"Thurner","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Clinical Immunology, Rheumatology, Medical School, University of Saarland, 66424 Homburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg Thomas","family":"Bittenbring","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Clinical Immunology, Rheumatology, Medical School, University of Saarland, 66424 Homburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Christofyllakis","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Clinical Immunology, Rheumatology, Medical School, University of Saarland, 66424 Homburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8832-252X","authenticated-orcid":false,"given":"Dominic","family":"Kaddu-Mulindwa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, Clinical Immunology, Rheumatology, Medical School, University of Saarland, 66424 Homburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"key":"ref_1","first-page":"2375","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/jncimonographs\/lgu013","article-title":"Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project","volume":"2014","author":"Morton","year":"2014","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.pathol.4.110807.092209","article-title":"Pathogenesis of Classical and Lymphocyte-Predominant Hodgkin Lymphoma","volume":"4","author":"Schmitz","year":"2009","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_4","unstructured":"(2021, August 02). Non-Hodgkin Lymphoma\u2014Cancer Stat Facts, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html."},{"key":"ref_5","first-page":"3724","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_6","first-page":"265","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMra0807082","article-title":"Aggressive Lymphomas","volume":"362","author":"Lenz","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_8","first-page":"1361","article-title":"A Revised European-American Classification of Lymphoid Neoplasms: A Proposal from the International Lymphoma Study Group","volume":"84","author":"Chan","year":"1994","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_9","first-page":"558","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/j.csbj.2020.07.008","article-title":"Methods for sequence and structural analysis of B and T cell receptor repertoires","volume":"18","author":"Teraguchi","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.it.2014.09.004","article-title":"Characterizing immune repertoires by high throughput sequencing: Strategies and applications","volume":"35","author":"Calis","year":"2014","journal-title":"Trends Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/ejh.12589","article-title":"The molecular pathogenesis of B-cell non-Hodgkin lymphoma","volume":"95","author":"Blombery","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/PPO.0000000000000447","article-title":"Molecular diagnostics of non-hodgkin lymphoma","volume":"26","author":"Solomon","year":"2020","journal-title":"Cancer J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ijc.2910220105","article-title":"Chromosome 14 translocations in non-burkitt lymphomas","volume":"22","author":"Fukuhara","year":"1978","journal-title":"Int. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/gene.2012.12","article-title":"The immunoglobulin heavy chain locus: Genetic variation, missing data, and implications for human disease","volume":"13","author":"Watson","year":"2012","journal-title":"Genes Immun."},{"key":"ref_16","first-page":"3884","article-title":"Understanding MYC-driven aggressive B-cell lymphomas: Pathogenesis and classification","volume":"122","author":"Ott","year":"2013","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5595","DOI":"10.1038\/sj.onc.1204595","article-title":"Translocations involving c-myc and c-myc function","volume":"20","author":"Boxer","year":"2001","journal-title":"Oncogene"},{"key":"ref_18","first-page":"105","article-title":"A bcl-2\/IgH antisense transcript deregulates bcl-2 gene expression in human follicular lymphoma t(14;18) cell lines","volume":"13","author":"Capaccioli","year":"1996","journal-title":"Oncogene"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cancergencyto.2003.08.008","article-title":"Detection of t(14;18) in follicular lymphoma by dual-color fluorescence in situ hybridization on paraffin-embedded tissue sections","volume":"150","author":"Matsumoto","year":"2004","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1309\/BLH8MMK85UBQ4K6R","article-title":"FISH Is Superior to PCR in Detecting t(14;18)(q32;q21)-IgH\/bcl-2 in Follicular Lymphoma Using Paraffin-Embedded Tissue Samples","volume":"124","author":"Einerson","year":"2005","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1182\/blood-2002-01-0263","article-title":"Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): Implications for pathogenesis","volume":"101","author":"Fend","year":"2003","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V88.4.1177.bloodjournal8841177","article-title":"Direct Visualization of Dispersed 11q13 Chromosomal Translocations in Mantle Cell Lymphoma by Multicolor DNA Fiber Fluorescence in situ Hybridization","volume":"88","author":"Vaandrager","year":"1996","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/CCO.0000000000000666","article-title":"Indications of next-generation sequencing in non-Hodgkin\u2019s lymphoma","volume":"32","author":"Heimann","year":"2020","journal-title":"Curr. Opin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF Mutations in Hairy-Cell Leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P Somatic Mutation in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3324\/haematol.2018.207928","article-title":"Burkitt-like lymphoma with 11q aberration: A germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma","volume":"104","author":"Villalobos","year":"2019","journal-title":"Haematologica"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ng.2828","article-title":"High prevalence of MAP2K1 mutations in variant and IGHV4-34\u2013expressing hairy-cell leukemias","volume":"46","author":"Waterfall","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_28","first-page":"391","article-title":"The exomic landscape of t(14;18)-negative diffuse follicular lymphoma with 1p36 deletion","volume":"180","author":"Pischimarov","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/humu.22552","article-title":"TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade","volume":"35","author":"Leroy","year":"2014","journal-title":"Hum. Mutat."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Xu, P., Liu, X., Ouyang, J., and Chen, B. (2017). TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence from a meta-analysis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0174809"},{"key":"ref_31","first-page":"3986","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: Report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Wu","year":"2012","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: A Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","author":"Shipp","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_36","first-page":"837","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"International CLL-IPI Working Group (2016). An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): A meta-analysis of individual patient data. Lancet Oncol., 17, 779\u2013790.","DOI":"10.1016\/S1470-2045(16)30029-8"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"435983","DOI":"10.1155\/2014\/435983","article-title":"Genetic Abnormalities in Chronic Lymphocytic Leukemia: Where We Are and Where We Go","volume":"2014","author":"Puiggros","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","author":"Salamero","year":"2010","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-019-0221-9","article-title":"Mutational processes contributing to the development of multiple myeloma","volume":"9","author":"Hoang","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","article-title":"Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies","volume":"33","author":"Scott","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal Gene Signatures in Large-B-Cell Lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1200\/JCO.2016.70.3660","article-title":"Clinical Impact of the Cell-of-Origin Classification and the MYC\/BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group","volume":"35","author":"Staiger","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: A report from the International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated with Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/leu.2015.43","article-title":"Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma","volume":"29","author":"Horn","year":"2015","journal-title":"Leukemia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41408-019-0208-6","article-title":"Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma","volume":"9","author":"Nowakowski","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular Subtypes of Diffuse Large B-cell Lymphoma are Associated with Distinct Pathogenic Mechanisms and Outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Bewarder, M., Stilgenbauer, S., Thurner, L., and Kaddu-Mulindwa, D. (2021). Current Treatment Options in CLL. Cancers, 13.","DOI":"10.3390\/cancers13102468"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for Patients with Chronic Lymphocytic Leukemia with 17p Deletion: Results from the Full Population of a Phase II Pivotal Trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): A phase 2, open-label, multicentre study","volume":"17","author":"Jones","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/bjh.15460","article-title":"Guideline for the treatment of chronic lymphocytic leukaemia","volume":"182","author":"Schuh","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_62","unstructured":"(2021, September 09). Chronische Lymphatische Leuk\u00e4mie (CLL)\u2014Onkopedia. Available online: https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/chronische-lymphatische-leukaemie-cll\/@@guideline\/html\/index.html."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in Previously Treated Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_64","first-page":"1637","article-title":"The genomic landscape of Waldenstr\u00f6m macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse Large B-Cell Lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: The critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/leu.2008.344","article-title":"Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24\/c-MYC translocations","volume":"23","author":"Niitsu","year":"2009","journal-title":"Leukemia"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood-2017-04-737320","article-title":"How I treat double-hit lymphoma","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjh.12982","article-title":"Double hit lymphoma: The MD Anderson Cancer Center clinical experience","volume":"166","author":"Oki","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood.V124.21.395.395","article-title":"Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma","volume":"124","author":"Dunleavy","year":"2014","journal-title":"Blood"},{"key":"ref_72","first-page":"108","article-title":"Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up \u2020","volume":"26","author":"Gaulard","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/bloodadvances.2020001581","article-title":"ALK-negative anaplastic large cell lymphoma: Features and outcomes of 235 patients from the International T-Cell Project","volume":"5","author":"Shustov","year":"2021","journal-title":"Blood Adv."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Klener, P., and Klanova, M. (2020). Drug Resistance in Non-Hodgkin Lymphomas. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062081"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance Mechanisms for the Bruton\u2019s Tyrosine Kinase Inhibitor Ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"11589","DOI":"10.1038\/ncomms11589","article-title":"Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition","volume":"7","author":"Burger","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies","volume":"36","author":"Liu","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1158\/1078-0432.CCR-18-3275","article-title":"Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma","volume":"25","author":"Prukova","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/bjh.15788","article-title":"Lymphoma diagnostics: Getting more from less","volume":"185","author":"Galardy","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/GIM.0b013e3181461c4a","article-title":"Challenges in array comparative genomic hybridization for the analysis of cancer samples","volume":"9","author":"Nowak","year":"2007","journal-title":"Genet. Med."},{"key":"ref_83","first-page":"45","article-title":"Microarray-based Comparative Genomic Hybridization (aCGH)","volume":"1","author":"Theisen","year":"2008","journal-title":"Nat. Educ."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1126\/science.270.5235.467","article-title":"Quantitative monitoring of gene expression patterns with a complementary DNA microarray","volume":"270","author":"Schena","year":"1995","journal-title":"Science"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.cancergen.2010.12.010","article-title":"High-resolution array comparative genomic hybridization (aCGH) identifies copy number alterations in diffuse large B-cell lymphoma that predict response to immuno-chemotherapy","volume":"204","author":"Kreisel","year":"2011","journal-title":"Cancer Genet."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Song, J., and Shao, H. (2015). SNP Array in Hematopoietic Neoplasms: A Review. Microarrays, 5.","DOI":"10.3390\/microarrays5010001"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep41400","article-title":"SNP variants associated with non-Hodgkin lymphoma (NHL) correlate with human leukocyte antigen (HLA) class II expression","volume":"7","author":"Ten","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/annonc\/mds646","article-title":"Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH","volume":"24","author":"Mian","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.exphem.2009.04.012","article-title":"Identified hidden genomic changes in mantle cell lymphoma using high-resolution single nucleotide polymorphism genomic array","volume":"37","author":"Kawamata","year":"2009","journal-title":"Exp. Hematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0022-2836(75)90213-2","article-title":"A Rapid Method for Determining Sequences in DNA by Primed Synthesis with DNA Polymerase","volume":"94","author":"Sanger","year":"1975","journal-title":"J. Mol. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/archdischild-2013-304340","article-title":"What is next generation sequencing?","volume":"98","author":"Behjati","year":"2013","journal-title":"Arch. Dis. Child Educ. Pract. Ed."},{"key":"ref_92","first-page":"3501","article-title":"IgH-V(D)J NGS-MRD measurement pre-and early post-allotransplant defines very low-and very high-risk ALL patients","volume":"125","author":"Pulsipher","year":"2015","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3389\/fonc.2019.00655","article-title":"MRD in AML: The Role of New Techniques","volume":"9","author":"Voso","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-L\u00e1zaro, D., Hern\u00e1ndez, J.L.G., Garc\u00eda, A.C., del Castillo, A.C., Hueso, M.V., and Cruz-Hern\u00e1ndez, J.J. (2020). Clinical perspective and translational oncology of liquid biopsy. Diagnostics, 10.","DOI":"10.3390\/diagnostics10070443"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3389\/fonc.2021.658234","article-title":"Clinical Application of Liquid Biopsy in Non-Hodgkin Lymphoma","volume":"11","author":"Lv","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000226740","article-title":"Neoplastic characteristics of the DNA found in the plasma of cancer patients","volume":"46","author":"Stroun","year":"1989","journal-title":"Oncology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"323","DOI":"10.7150\/jca.6226","article-title":"Plasma Cell-Free DNA in Paediatric Lymphomas","volume":"4","author":"Mussolin","year":"2013","journal-title":"J. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1200\/JCO.2010.32.8161","article-title":"Minimal Disseminated Disease in High-Risk Burkitt\u2019s Lymphoma Identifies Patients with Different Prognosis","volume":"29","author":"Mussolin","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3109\/10428191003746331","article-title":"Circulating cell-free and Epstein\u2013Barr virus DNA in pediatric B-non-Hodgkin lymphomas","volume":"51","author":"Machado","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/hon.2587","article-title":"Liquid biopsy in non-Hodgkin\u2019s lymphoma","volume":"37","author":"Melani","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1586\/14737159.2015.1019476","article-title":"Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq","volume":"15","author":"Bratman","year":"2015","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Lymphoid Neoplasia: Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: A correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood.V126.23.2675.2675","article-title":"Quantitative Assessment of Circulating Clonal IG-VDJ Sequences in Plasma of Follicular Lymphoma at Diagnosis Is Highly Predictive of Progression Free Survival (PFS)","volume":"126","author":"Sarkozy","year":"2015","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1182\/blood.V118.21.2542.2542","article-title":"High-Throughput Immunoglobulin Gene Sequencing Quantifies Minimal Residual Disease in CLL with 10e-6 Sensitivity and Strongly Predicts Relapse After Allogeneic Hematopoietic Cell Transplantation","volume":"118","author":"Logan","year":"2011","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2013","journal-title":"Leukemia"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/hematology.2019000013","article-title":"Prognostication with circulating tumor DNA: Is it ready for prime time?","volume":"2019","author":"Kurtz","year":"2019","journal-title":"Hematology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1182\/blood-2019-132069","article-title":"Towards Non-Invasive Classification of DLBCL Genetic Subtypes by Ctdna Profiling","volume":"134","author":"Esfahani","year":"2019","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1200\/JCO.2017.35.15_suppl.7507","article-title":"Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma","volume":"35","author":"Jin","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-018-0111-6","article-title":"Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: Analysis of a prospective cohort","volume":"8","author":"Bohers","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1038\/s41379-020-0575-3","article-title":"Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: Expanding the landscape of EBV-related lymphomas","volume":"33","author":"Mundo","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/bloodadvances.2016002618","article-title":"Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma","volume":"1","author":"Welch","year":"2017","journal-title":"Blood Adv."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood-2012-09-454694","article-title":"Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: Correlative analysis from a large North American cooperative group trial","volume":"121","author":"Kanakry","year":"2013","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/leu.2013.212","article-title":"Quantification of circulating Epstein\u2013Barr virus DNA in NK\/T-cell lymphoma treated with the SMILE protocol: Diagnostic and prognostic significance","volume":"28","author":"Kwong","year":"2013","journal-title":"Leukemia"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/leu.2017.91","article-title":"The emerging roles of tumor-derived exosomes in hematological malignancies","volume":"31","author":"Boyiadzis","year":"2017","journal-title":"Leukemia"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/ncb1596","article-title":"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells","volume":"9","author":"Valadi","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1517\/14712598.2016.1131976","article-title":"Exosomes for repair, regeneration and rejuvenation","volume":"16","author":"Basu","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"102825","DOI":"10.1016\/j.critrevonc.2019.102825","article-title":"The opportunistic effect of exosomes on Non-Hodgkin Lymphoma microenvironment modulation","volume":"144","author":"Fernandes","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.blre.2015.01.004","article-title":"Information transfer by exosomes: A new frontier in hematologic malignancies","volume":"29","author":"Boyiadzis","year":"2015","journal-title":"Blood Rev."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Navarro-Tableros, V., Gomez, Y., Camussi, G., and Brizzi, M.F. (2018). Extracellular Vesicles: New Players in Lymphomas. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20010041"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2174\/1389202916666150707160147","article-title":"MicroRNAs in Lymphoma: Regulatory Role and Biomarker Potential","volume":"16","author":"Manterola","year":"2015","journal-title":"Curr. Genom."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/227561a0","article-title":"Central Dogma of Molecular Biology","volume":"227","author":"Crick","year":"1970","journal-title":"Nature"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00277-011-1350-9","article-title":"Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma","volume":"91","author":"Fang","year":"2011","journal-title":"Ann. Hematol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/leu.2014.351","article-title":"MicroRNAs in B-cell lymphomas: How a complex biology gets more complex","volume":"29","author":"Musilova","year":"2014","journal-title":"Leukemia"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/embo-reports\/kve230","article-title":"Non-coding RNAs: The architects of eukaryotic complexity","volume":"2","author":"Mattick","year":"2001","journal-title":"EMBO Rep."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Nonlinear partial differential equations and applications: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/bjh.13043","article-title":"Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia","volume":"167","author":"Lin","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.it.2020.08.006","article-title":"miRNA-Based Therapies in B Cell Non-Hodgkin Lymphoma","volume":"41","author":"Fuertes","year":"2020","journal-title":"Trends Immunol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/ijc.22800","article-title":"Microrna expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma","volume":"121","author":"Lawrie","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00277-014-2111-3","article-title":"Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients","volume":"93","author":"Song","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"9637","DOI":"10.1038\/s41598-020-66062-1","article-title":"The value of circulating microRNAs for early diagnosis of B-cell lymphoma: A case-control study on historical samples","volume":"10","author":"Paulsen","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic\u2014Implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/11\/12\/2174\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:34:47Z","timestamp":1760168087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/11\/12\/2174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,23]]},"references-count":135,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["diagnostics11122174"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics11122174","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,23]]}}}